NeoPred, a dual-phase CT AI tool, accurately predicts major pathological response in NSCLC patients preoperatively.
Key Details
- 1NeoPred combines pre-treatment and pre-surgery CT scans with clinical data to predict major pathological response (MPR) in NSCLC undergoing neoadjuvant chemo-immunotherapy.
- 2Study included 509 patients across four oncology centers (459 retrospective, 50 prospective, 59 external validation).
- 3NeoPred reached AUCs of 0.772 (imaging only) and 0.787 (imaging plus clinical data) on external validation, outperforming thoracic surgeons (AUC 0.760 vs 0.720) in prospective testing.
- 4AI support improved surgeons' AUC to 0.829 and diagnostic accuracy to 82%.
- 5NeoPred identified 'pseudo-stable' responders missed by standard RECIST criteria, with AUCs of 0.742 (external) and 0.833 (prospective).
Why It Matters
Accurately predicting response before surgery could enable earlier, evidence-based clinical decisions for NSCLC, reducing overtreatment and personalizing care. This work demonstrates the expanding role and performance advantage of AI-assisted imaging over traditional assessment in complex oncologic management.
Source
EurekAlert
Related News
•EurekAlert
AI Model Accurately Predicts Blood Loss Risk in Liposuction
A machine learning model predicts blood loss during high-volume liposuction with 94% accuracy.
•EurekAlert
AI-Driven CT Tool Predicts Cancer Spread in Oropharyngeal Tumors
Researchers have created an AI tool that uses CT imaging to predict the spread risk of oropharyngeal cancer, offering improved treatment stratification.
•EurekAlert
AI Model PRTS Predicts Spatial Transcriptomics From H&E Histology Images
Researchers developed PRTS, a deep learning model that infers single-cell spatial transcriptomics from standard H&E-stained tissue images.